{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:39Z","timestamp":1790794779708,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Vulvar squamous cell carcinoma (vSCC), although rare, carries significant morbidity and a high rate of recurrence. Treatment options beyond surgical excision remain limited. Lymphocyte activation gene-3 (LAG-3) and its binding partner galectin-3 (GAL-3) are an immuno-inhibitory checkpoint pair that represent potential immunotherapy targets for the treatment of vSCC. This study examined the expression of LAG-3 and GAL-3 alongside programmed cell death ligand-1 expression in invasive SCC and vulvar intraepithelial neoplasia (VIN) by immunohistochemical analysis of formalin-fixed paraffin-embedded tissue. A total of 35 cases were selected for evaluation: 13 VIN3 [human papillomavirus (HPV)-associated VIN\/usual-type VIN], 2 differentiated VIN (dVIN), 16 HPV-associated vSCC, and 4 dVIN-associated vSCC. LAG-3+ tumor-infiltrating lymphocytes were identified in 91% (32\/35) of cases of vulvar squamous neoplasia. Tumor cells were positive for GAL-3 in 71% of the vulvar neoplasia cases. HPV-associated vSCC was more likely to demonstrate GAL-3 tumoral positivity when compared with dVIN-associated vSCC (24\/29 vs. 1\/6, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.004). We observed co-expression of all 3 immunomarkers in 40% (14\/35) of cases evaluated. In light of these findings, use of immunomodulatory drugs that target the LAG-3\/GAL-3 pathway may be potentially beneficial in vSCC and efficacy may be increased when combined with anti-programmed cell death ligand-1 therapy.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000782","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T01:01:03Z","timestamp":1617066063000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia"],"prefix":"10.1097","volume":"41","author":[{"given":"Margaret M.","family":"Cocks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"suppl 2","key":"R1-20250802","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ijgo.12609","article-title":"Cancer of the vulva","volume":"143","author":"Rogers","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ogc.2018.09.008","article-title":"Vulvar cancer","volume":"46","author":"Weinberg","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000454","article-title":"squamous cell carcinoma of the vulva: a subclassification of 97 cases by clinicopathologic, immunohistochemical, and molecular features (p16, p53, and EGFR)","volume":"39","author":"Dong","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/PGP.0000000000000280","article-title":"The natural history of vulvar intraepithelial neoplasia, differentiated type: evidence for progression and diagnostic challenges","volume":"35","author":"Bigby","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2018.10.015","article-title":"The prognostic value of p16 and p53 expression for survival after vulvar cancer: a systematic review and meta-analysis","volume":"152","author":"Sand","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/his.13205","article-title":"Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study","volume":"71","author":"McAlpine","year":"2017","journal-title":"Histopathology"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.05.019","article-title":"Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy","volume":"142","author":"Lee","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJWH.S68979","article-title":"Vulvar cancer: epidemiology, clinical presentation, and management options","volume":"7","author":"Alkatout","year":"2015","journal-title":"Int J Womens Health"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.007","article-title":"Risk factors and treatment for recurrent vulvar squamous cell carcinoma","volume":"106","author":"Nooij","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMc1510353","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"373","author":"Asaoka","year":"2015","journal-title":"N Engl J Med"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"e28325","DOI":"10.4161\/onci.28325","article-title":"Immune checkpoints: a therapeutic target in triple negative breast cancer","volume":"3","author":"Chawla","year":"2014","journal-title":"Oncoimmunology"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R17-20250802","doi-asserted-by":"crossref","first-page":"TPS789","DOI":"10.1200\/jco.2016.34.4_suppl.tps789","article-title":"KEYNOTE-177: first-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma","volume":"34","author":"Diaz","year":"2016","journal-title":"J Clin Oncol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/his.13723","article-title":"PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy","volume":"74","author":"Chinn","year":"2019","journal-title":"Histopathology"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results From the Phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"92890","DOI":"10.18632\/oncotarget.21641","article-title":"Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology","volume":"8","author":"Hecking","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000491090","article-title":"Pembrolizumab in recurrent squamous cell carcinoma of the vulva: case report and review of the literature","volume":"84","author":"Shields","year":"2019","journal-title":"Gynecol Obstet Invest"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"Lymphocyte-activation gene-3, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J Immunol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R30-20250802","first-page":"269","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J Immunol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T Cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"e1434467","DOI":"10.1080\/2162402X.2018.1434467","article-title":"The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment","volume":"7","author":"Farhad","year":"2018","journal-title":"Oncoimmunology"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.09.003","article-title":"Galectin-3\u2014a jack-of-all-trades in cancer","volume":"313","author":"Newlaczyl","year":"2011","journal-title":"Cancer Lett"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12935-018-0668-y","article-title":"Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.2147\/CMAR.S171146","article-title":"Galectin-3 and \u03b2-catenin are associated with a poor prognosis in serous epithelial ovarian cancer","volume":"10","author":"Liu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.prp.2017.01.012","article-title":"Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas","volume":"213","author":"Al-Maghrabi","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"e1440930","DOI":"10.1080\/2162402X.2018.1440930","article-title":"Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma","volume":"7","author":"Wu","year":"2018","journal-title":"Oncoimmunology"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1186\/s12885-018-4726-6","article-title":"Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas","volume":"18","author":"Wehrhan","year":"2018","journal-title":"BMC Cancer"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0000000000000608","article-title":"LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy","volume":"39","author":"Friedman","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"16956","DOI":"10.1038\/s41598-017-17034-5","article-title":"Assessment of concordance between 22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in non-small cell lung cancer","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.7150\/jca.26949","article-title":"Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma","volume":"9","author":"Zhang","year":"2018","journal-title":"J Cancer"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-018-0418-7","article-title":"A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy","volume":"6","author":"Duan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1\/PD-L1 and tumor-infiltrating lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R51-20250802","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12253-013-9603-7","article-title":"Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt\/beta-catenin-dependent pathway","volume":"19","author":"Wang","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/s12885-017-3920-2","article-title":"Galectin 3 expression in primary oral squamous cell carcinomas","volume":"17","author":"Weber","year":"2017","journal-title":"BMC Cancer"},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.pgp.0000179613.40215.c0","article-title":"Galectin-3 and CD1a-positive dendritic cells are involved in the development of an invasive phenotype in vulvar squamous lesions","volume":"25","author":"Brustmann","year":"2006","journal-title":"Int J Gynecol Pathol"},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/MLG.0b013e31817b0718","article-title":"Galectin-3 upregulation during tumor progression in head and neck cancer","volume":"118","author":"Saussez","year":"2008","journal-title":"Laryngoscope"},{"key":"R55-20250802","first-page":"59","article-title":"Expression of galectin-3-reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation","volume":"19","author":"Plzak","year":"2001","journal-title":"Int J Oncol"},{"key":"R56-20250802","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"key":"R57-20250802","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0959-8049(01)00184-8","article-title":"T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3\/MHC class II interactions in cell-cell contacts","volume":"37","author":"Demeure","year":"2001","journal-title":"Eur J Cancer"},{"key":"R58-20250802","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"R59-20250802","doi-asserted-by":"crossref","first-page":"81341","DOI":"10.18632\/oncotarget.13228","article-title":"Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors","volume":"7","author":"Mishra","year":"2016","journal-title":"Oncotarget"},{"key":"R60-20250802","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"R61-20250802","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00428-018-2364-7","article-title":"PD-L1 receptor expression in vulvar carcinomas is HPV-independent","volume":"473","author":"Choschzick","year":"2018","journal-title":"Virch Archiv"},{"key":"R62-20250802","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"key":"R63-20250802","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cllc.2017.12.001","article-title":"LAG-3 in non-small-cell lung cancer: expression in primary tumors and metastatic lymph nodes is associated with improved survival","volume":"19","author":"Hald","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:44Z","timestamp":1754161424000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000782","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}